No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BFRI Biofrontera
- 1.0550
- -0.0450-4.09%
Close Jul 12 16:00 ET
- 1.0500
- -0.0050-0.47%
Post 19:49 ET
5.37MMarket Cap-102P/E (TTM)
1.1000High1.0450Low50.36KVolume1.1000Open1.1000Pre Close53.90KTurnover1.92%Turnover RatioLossP/E (Static)5.09MShares12.985752wk High-0.99P/B2.77MFloat Cap0.610052wk Low--Dividend TTM2.63MShs Float292.6000Historical High--Div YieldTTM5.00%Amplitude0.6100Historical Low1.0700Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable?
Express News | Biofrontera Shares Are Trading Higher After the Company Launched the RhodoLED XL Lamp
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED XL Lamp
The RhodoLED XL is approved by the FDA in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face
Does The Market Have A Low Tolerance For Biofrontera AG's (ETR:B8FK) Mixed Fundamentals?
Benchmark Co. Maintains Biofrontera(BFRI.US) With Buy Rating, Maintains Target Price $7
Benchmark Co. analyst Bruce Jackson maintains $Biofrontera(BFRI.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 29.9% and a t
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
Comments
$Biofrontera(BFRI.US$ WOBURN MA / ACCESSWIRE / May 3, 2024 / WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the Board of Directors has met and certified that two criteria described in warrants to purchase Series B-3 Convertible Preferred Stock issued by the Company on February 22, 2024 (the "Warrants") have been ful...
1
$Biofrontera(BFRI.US$ Biofrontera posts record revenue and outlines growth plans
$Biofrontera(BFRI.US$ Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Accesswire·
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules
Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth
Accesswire·
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules
Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth
1
1
7
$Biofrontera(BFRI.US$ And another! hehehe! hope my rope holds🦘
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg